Last week, the U.S. Food and Drug Administration granted initial approval for an investigational monoclonal drug COVID-19, paving the way for more widespread use of the promising antibody-based treatment in the coming months. Taken in tandem with Pfizer announcing that its main coronavirus vaccine candidate had been 90% effective in advanced trials, it was good news in a country experiencing well over 100,000 new cases of COVID-19 per day.
But the bottlenecks will likely slow down doctors’ efforts to include monoclonal antibodies in the standard of care for COVID-19. The weeks and months ahead will be a race to develop smart ways to increase the production and distribution of these therapies even as hospitals are overwhelmed and deaths spiral.
welcome to Rabbit hole, where we dive deep into the bigger story. This is reserved for members of Beast Inside. Join us today.
#Eli #Lilly #antibody #coming #late